
KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
Drug Topics articles
- <![CDATA[The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025]]> October 18, 2025
- <![CDATA[How Community Pharmacists Are Proactively Managing Patients’ Migraines | NCPA 2025]]> October 18, 2025
- <![CDATA[Severe COVID-19 Increases Stroke Risk for Patients With Asthma]]> October 17, 2025
- <![CDATA[Guidelines Are Key for Treating Substance Use Disorder]]> October 17, 2025
- <![CDATA[FDA Approves Expanded Indications for Adalimumab-Aaty for Pediatric Indications]]> October 17, 2025
- <![CDATA[Pharmacists Help Patients Stay Adherent to COPD Therapy, Improving Overall Quality of Life]]> October 17, 2025
- <![CDATA[American Pharmacists Month: Pharmacy Education Adapting to Evolving Pharmacist Profession]]> October 16, 2025
- <![CDATA[Interactive Test Understanding Flublok® (Influenza Vaccine)]]> October 16, 2025
- <![CDATA[Orforglipron Demonstrates Superior Glycemic Control for Type 2 Diabetes]]> October 16, 2025
- <![CDATA[Provider Judgment On Cannabis Use During Pregnancy Causes Patient Mistrust]]> October 16, 2025
Pharmacy Times articles
- <![CDATA[Addressing Drug Resistance in Lung Cancer ]]> October 18, 2025
- <![CDATA[From Mutation to Medicine: Targeted Therapies in Lung Cancer]]> October 18, 2025
- <![CDATA[TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC]]> October 18, 2025
- <![CDATA[Expert Discusses Early Safety and Tolerability Findings for VMT-α-NET in Neuroendocrine Tumors | ESMO 2025]]> October 18, 2025
- <![CDATA[Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer]]> October 17, 2025
- <![CDATA[Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer]]> October 17, 2025
- <![CDATA[Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer]]> October 17, 2025
- <![CDATA[The Juggling Act: Navigating Pharmacy School and Parenting]]> October 17, 2025
- <![CDATA[Emerging Use of an Allosteric TKI: Asciminib for the Treatment of Chronic Myeloid Leukemia]]> October 17, 2025
- <![CDATA[Pharmacists Are Indispensable in Managing Chronic Kidney Disease]]> October 17, 2025

Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com